

## **PolyPid Announces Presentation of D-PLEX Phase 2 Clinical Data at ASM Microbe 2022**

*Phase 2 clinical data on the efficacy of D-PLEX<sub>100</sub> in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation*

PETACH TIKVA, Israel, June 06, 2022 — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that data from a previously completed Phase 2 clinical trial of D-PLEX<sub>100</sub> will be highlighted in a presentation at the upcoming American Microbiology Society (ASM) Microbe 2022, being held on June 9-13, 2022, in Washington, D.C.

The abstract, *‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’* evaluates the effect of D-PLEX<sub>100</sub> in combination with surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The data will be presented by Judith Steenberg, Ph.D., President of Scientific and Medical Affairs Consulting (SMAC). The abstract will be available on <https://www.polypid.com/> following the presentation.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX<sub>100</sub> is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

### **Corporate Contact:**

PolyPid Ltd.  
Dikla Czaczkes Akselbrad  
EVP & CFO  
Tel: +972-747195700

**Investor Contact:**

Bob Yedid

LifeSci Advisors

646-597-6989

Bob@LifeSciAdvisors.com

**Media Contact:**

Nechama Feuerstein

FINN Partners

551-444-0784

Nechama.Feuerstein@finnpartners.com

